Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50-64 Years of Age. - Poder A; Oberije J; Meyer J; Heymer P; Molrine D; Versage E; Isakov L; Zhang Q; Hohenboken M (Vaccines, 2023)